Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 3, 2015, Pages 323-330

  Kooiman, Judith ^a   den Exter, Paul L ^a   Kilicsoy, Inci ^a   Cannegieter, Suzanne C ^a   Eikenboom, Jeroen ^a   Huisman, Menno V ^a   Klok, Frederikus A ^a   Versteeg, Henri H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Factor VIII activity; Micro particle tissue factor; Pulmonary embolism; Recurrent venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 8; MICROPARTICLE TISSUE FACTOR; THROMBOPLASTIN; UNCLASSIFIED DRUG; F8 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; ACUTE DISEASE; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; MEMBRANE MICROPARTICLE; METABOLISM; MULTICENTER STUDY;

ACUTE DISEASE; ADULT; AGED; CELL-DERIVED MICROPARTICLES; FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 84940437643     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1180-z     Document Type: Article

References (36)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938
2. Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657–660
3. Carrier M, Le Gal G, Wells PS, Rodger MA (2010) Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152:578–589
4. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7
5. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907
6. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332:1661–1665
7. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428
8. Owens AP III, Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108:1284–1297
9. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP (2005) Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 105:192–198
10. Zhou J, May L, Liao P, Gross PL, Weitz JI (2009) Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol 29:863–869
11. Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD Jr, Henke PK, Wakefield TW (2009) Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 101:748–754
12. Himber J, Wohlgensinger C, Roux S, Damico LA, Fallon JT, Kirchhofer D, Nemerson Y, Riederer MA (2003) Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 1:889–895
13. Garcia RP, Eikenboom HC, Tesselaar ME, Huisman MV, Nijkeuter M, Osanto S, Bertina RM (2010) Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res 126:345–349
14. Ye R, Ye C, Huang Y, Liu L, Wang S (2012) Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res 130:253–258
15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293:2352–2361
16. Cosmi B, Legnani C, Cini M, Favaretto E, Palareti G (2008) D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res 122:610–617
17. Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P (2004) High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 124:504–510
18. Kraaijenhagen RA, Anker PS, Koopman MM, Reitsma PH, Prins MH, Van den Ende A, Buller HR (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83:5–9
19. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343:457–462
20. Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, Bauer KA, Kessler CM, Cushman M (2006) D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 4:1208–1214
21. Klok FA, Zondag W, van Kralingen KW, van Dijk AP, Tamsma JT, Heyning FH, Vliegen HW, Huisman MV (2010) Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 181:501–506
22. Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV (2010) Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 95:970–975
23. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527
24. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722
25. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815
26. Kasthuri RS, Taubman MB, Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol 27:4834–4838
27. Tesselaar ME, Romijn FP, Van Der Linden IK, Bertina RM, Osanto S (2009) Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 7:1421–1423
28. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830–6840
29. Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM, Leebeek FW (2011) Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 105:14–20
30. Hernandez C, Orbe J, Roncal C, Alvarez-Hernandez M, de Martinez LS, Alves MT, Garcia MJ, Paramo JA (2013) Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 110:598–608
31. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, Zielinski C, Pabinger I (2012) Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 10:1363–1370
32. Steppich BA, Hassenpflug M, Braun SL, Schomig K, von Beckerath O, von Beckerath N, Eckstein HH, Ott I (2011) Circulating tissue factor and microparticles are not increased in patients with deep vein thrombosis. Vasa 40:117–122
33. Reitsma PH, Versteeg HH, Middeldorp S (2012) Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 32:563–568
34. Cannegieter SC, VAN VH (2013) Venous thrombosis: understanding the paradoxes of recurrence. J Thromb Haemost 11(Suppl 1):161–169
35. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–155
36. Jenkins PV, Rawley O, Smith OP, O’Donnell JS (2012) Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 157:653–663